T cell exhaustion and Interleukin 2 downregulation

Cytokine

Volumn 71, Issue 2, 2015, Pages 339-347

  Balkhi, Mumtaz Y ^a   Ma, Qiangzhong ^a   Ahmad, Shazia ^b   Junghans, Richard P ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chromatin; Exhaustion; Interleukin 2; PD1; T cells

Indexed keywords

INTERLEUKIN 2; TUMOR ANTIGEN; 3' UNTRANSLATED REGION; CHROMATIN; MESSENGER RNA;

3' UNTRANSLATED REGION; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PARASITOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE EXHAUSTION; TH1 CELL; TH2 CELL; VIRUS INFECTION; ANIMAL; APOPTOSIS; BIOLOGY; CELL DIFFERENTIATION; CHROMATIN; CYTOLOGY; DOWN REGULATION; GENETIC EPIGENESIS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BACTERIAL INFECTIONS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHROMATIN; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; PARASITIC DISEASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84921277700     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.024     Document Type: Review

References (136)

1. Schwartz R.H. T cell anergy. Annu Rev Immunol 2003, 21:305-334.
2. Schietinger A., Greenberg P.D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014, 35:51-60.
3. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
4. Yi J.S., Cox M.A., Zajac A.J. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010, 129:474-481.
5. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998, 188:2205-2213.
6. Fuller M.J., Khanolkar A., Tebo A.E., Zajac A.J. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol 2004, 172:4204-4214.
7. Grosso J.F., Goldberg M.V., Getnet D., Bruno T.C., Yen H.R., Pyle K.J., et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009, 182:6659-6669.
8. Matsuzaki J., Gnjatic S., Mhawech-Fauceglia P., Beck A., Miller A., Tsuji T., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010, 107:7875-7880.
9. Wherry E.J. T cell exhaustion. Nat Immunol 2011, 12:492-499.
10. Speiser D.E. A molecular profile of T-cell exhaustion in cancer. Oncoimmunology 2012, 1:369-371.
11. Atkins M.B., Elder D.E., Essner R., Flaherty K.T., Gajewski T.F., Haluska F.G., et al. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006, 12:2291s-2296s.
12. Kim M.V., Ouyang W., Liao W., Zhang M.Q., Li M.O. The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Immunity 2013, 39:286-297.
13. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012, 12:749-761.
14. Crawford A., Angelosanto J.M., Kao C., Doering T.A., Odorizzi P.M., Barnett B.E., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 2014, 40:289-302.
15. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
16. Baitsch L., Baumgaertner P., Devevre E., Raghav S.K., Legat A., Barba L., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 2011, 121:2350-2360.
17. Baumgaertner P., Jandus C., Rivals J.P., Derre L., Lovgren T., Baitsch L., et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 2012, 130:2607-2617.
18. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
19. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
20. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A 2008, 105:20428-20433.
21. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008, 205:543-555.
22. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461-2472.
23. Moskophidis D., Lechner F., Pircher H., Zinkernagel R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
24. Richter K., Brocker T., Oxenius A. Antigen amount dictates CD8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell. Eur J Immunol 2012, 42:2290-2304.
25. Mueller S.N., Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2009, 106:8623-8628.
26. Day C.L., Kiepiela P., Leslie A.J., van der Stok M., Nair K., Ismail N., et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007, 81:434-438.
27. Klenerman P., Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005, 6:873-879.
28. Goepfert P.A., Bansal A., Edwards B.H., Ritter G.D., Tellez I., McPherson S.A., et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 2000, 74:10249-10255.
29. Obar J.J., Fuse S., Leung E.K., Bellfy S.C., Usherwood E.J. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol 2006, 80:8303-8315.
30. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
31. Han S., Asoyan A., Rabenstein H., Nakano N., Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci U S A 2010, 107:20453-20458.
32. Chandele A., Mukerjee P., Das G., Ahmed R., Chauhan V.S. Phenotypic and functional profiling of malaria-induced CD8 and CD4 T cells during blood-stage infection with Plasmodium yoelii. Immunology 2011, 132:273-286.
33. Wykes M.N., Horne-Debets J.M., Leow C.Y., Karunarathne D.S. Malaria drives T cells to exhaustion. Front Microbiol 2014, 5:249.
34. Horne-Debets J.M., Faleiro R., Karunarathne D.S., Liu X.Q., Lineburg K.E., Poh C.M., et al. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep 2013, 5:1204-1213.
35. Butler N.S., Moebius J., Pewe L.L., Traore B., Doumbo O.K., Tygrett L.T., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012, 13:188-195.
36. Esch K.J., Juelsgaard R., Martinez P.A., Jones D.E., Petersen C.A. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol 2013, 191:5542-5550.
37. Mou Z., Muleme H.M., Liu D., Jia P., Okwor I.B., Kuriakose S.M., et al. Parasite-derived arginase influences secondary anti-Leishmania immunity by regulating programmed cell death-1-mediated CD4+ T cell exhaustion. J Immunol 2013, 190:3380-3389.
38. Hernandez-Ruiz J., Salaiza-Suazo N., Carrada G., Escoto S., Ruiz-Remigio A., Rosenstein Y., et al. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis 2010, 4:e871.
39. Bhadra R., Khan I.A. Redefining chronic toxoplasmosis - a T cell exhaustion perspective. PLoS Pathog 2012, 8:e1002903.
40. Bhadra R., Gigley J.P., Weiss L.M., Khan I.A. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci U S A 2011, 108:9196-9201.
41. Singh A., Mohan A., Dey A.B., Mitra D.K. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013, 208:603-615.
42. Reiley W.W., Shafiani S., Wittmer S.T., Tucker-Heard G., Moon J.J., Jenkins M.K., et al. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 2010, 107:19408-19413.
43. Perreau M., Vigano S., Bellanger F., Pellaton C., Buss G., Comte D., et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J Exp Med 2014, 211:2033-2045.
44. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
45. Chin L., Hahn W.C., Getz G., Meyerson M. Making sense of cancer genomic data. Genes Dev 2011, 25:534-555.
46. Preiss S., Kammertoens T., Lampert C., Willimsky G., Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer 2005, 115:456-462.
47. Blankenstein T., Coulie P.G., Gilboa E., Jaffee E.M. The determinants of tumour immunogenicity. Nat Rev Cancer 2012, 12:307-313.
48. Andersen R.S., Thrue C.A., Junker N., Lyngaa R., Donia M., Ellebaek E., et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012, 72:1642-1650.
49. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 2004, 114:551-559.
50. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-1151.
51. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002, 99:351-358.
52. Helt A.M., Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003, 24:159-169.
53. Powell D.J., Eisenlohr L.C., Rothstein J.L. A thyroid tumor-specific antigen formed by the fusion of two self proteins. J Immunol 2003, 170:861-869.
54. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103:1037-1042.
55. Cai A., Keskin D.B., DeLuca D.S., Alonso A., Zhang W., Zhang G.L., et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res 2012, 18:5761-5772.
56. Brown S.D., Warren R.L., Gibb E.A., Martin S.D., Spinelli J.J., Nelson B.H., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014, 24:743-750.
57. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J 2013, 32:194-203.
58. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
59. Mumprecht S., Schurch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114:1528-1536.
60. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005, 102:16013-16018.
61. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314.
62. Peters B., Sidney J., Bourne P., Bui H.H., Buus S., Doh G., et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005, 3:e91.
63. Vita R., Zarebski L., Greenbaum J.A., Emami H., Hoof I., Salimi N., et al. The immune epitope database 2.0. Nucl Acid Res 2010, 38:D854-D862.
64. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
65. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
66. Lo A.S., Ma Q., Liu D.L., Junghans R.P. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010, 16:2769-2780.
67. Heemskerk B., Liu K., Dudley M.E., Johnson L.A., Kaiser A., Downey S., et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008, 19:496-510.
68. Lotze M.T., Matory Y.L., Ettinghausen S.E., Rayner A.A., Sharrow S.O., Seipp C.A., et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985, 135:2865-2875.
69. Davis M.M. A new trigger for T cells. Cell 2002, 110:285-287.
70. Molina T.J., Kishihara K., Siderovski D.P., van Ewijk W., Narendran A., Timms E., et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992, 357:161-164.
71. Van Laethem F., Tikhonova A.N., Pobezinsky L.A., Tai X., Kimura M.Y., Le Saout C., et al. Lck availability during thymic selection determines the recognition specificity of the T cell repertoire. Cell 2013, 154:1326-1341.
72. Hussain A., Mohammad D.K., Gustafsson M.O., Uslu M., Hamasy A., Nore B.F., et al. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70. J Biol Chem 2013, 288:7338-7350.
73. Gong Q., Cheng A.M., Akk A.M., Alberola-Ila J., Gong G., Pawson T., et al. Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. Nat Immunol 2001, 2:29-36.
74. Margarit S.M., Sondermann H., Hall B.E., Nagar B., Hoelz A., Pirruccello M., et al. Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 2003, 112:685-695.
75. Kortum R.L., Balagopalan L., Alexander C.P., Garcia J., Pinski J.M., Merrill R.K., et al. The ability of Sos1 to oligomerize the adaptor protein LAT is separable from its guanine nucleotide exchange activity in vivo. Sci Signal 2013, 6:ra99.
76. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426.
77. Kang Y.J., Seit-Nebi A., Davis R.J., Han J. Multiple activation mechanisms of p38alpha mitogen-activated protein kinase. J Biol Chem 2006, 281:26225-26234.
78. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
79. Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994, 78:1039-1049.
80. Alberola-Ila J., Forbush K.A., Seger R., Krebs E.G., Perlmutter R.M. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 1995, 373:620-623.
81. Cantrell D.A. T cell antigen receptor signal transduction pathways. Cancer Surv 1996, 27:165-175.
82. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
83. Kim H.P., Imbert J., Leonard W.J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006, 17:349-366.
84. Putney J.W. Pharmacology of store-operated calcium channels. Mol Interv 2010, 10:209-218.
85. Ye Q., Feng Y., Yin Y., Faucher F., Currie M.A., Rahman M.N., et al. Structural basis of calcineurin activation by calmodulin. Cell Signal 2013, 25:2661-2667.
86. Rumi-Masante J., Rusinga F.I., Lester T.E., Dunlap T.B., Williams T.D., Dunker A.K., et al. Structural basis for activation of calcineurin by calmodulin. J Mol Biol 2012, 415:307-317.
87. Muller M.R., Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010, 10:645-656.
88. Hogan P.G., Chen L., Nardone J., Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003, 17:2205-2232.
89. Park S.G., Schulze-Luehrman J., Hayden M.S., Hashimoto N., Ogawa W., Kasuga M., et al. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol 2009, 10:158-166.
90. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009, 229:12-26.
91. Rudd C.E., Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003, 3:544-556.
92. Raab M., Cai Y.C., Bunnell S.C., Heyeck S.D., Berg L.J., Rudd C.E. P56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci U S A 1995, 92:8891-8895.
93. Bocko D., Kosmaczewska A., Ciszak L., Teodorowska R., Frydecka I. CD28 costimulatory molecule-expression, structure and function. Arch Immunol Ther Exp (Warsz) 2002, 50:169-177.
94. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003, 3:317-330.
95. Bustelo X.R. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000, 20:1461-1477.
96. Kane L.P., Andres P.G., Howland K.C., Abbas A.K., Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2001, 2:37-44.
97. Kane L.P., Shapiro V.S., Stokoe D., Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999, 9:601-604.
98. Riley J.L. PD-1 signaling in primary T cells. Immunol Rev 2009, 229:114-125.
99. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25:9543-9553.
100. Cuddapah S., Barski A., Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol 2010, 22:341-347.
101. Youngblood B., Noto A., Porichis F., Akondy R.S., Ndhlovu Z.M., Austin J.W., et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 2013, 191:540-544.
102. Lee G.R., Kim S.T., Spilianakis C.G., Fields P.E., Flavell R.A. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 2006, 24:369-379.
103. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
104. Li Q.J., Chau J., Ebert P.J., Sylvester G., Min H., Liu G., et al. MiR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129:147-161.
105. Chen G., Cao P., Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002, 9:401-410.
106. Van Etten J., Schagat T.L., Hrit J., Weidmann C.A., Brumbaugh J., Coon J.J., et al. Human pumilio proteins recruit multiple deadenylases to efficiently repress messenger RNAs. J Biol Chem 2012, 287:36370-36383.
107. Triboulet R., Gregory R.I. Pumilio turns on microRNA function. Nat Cell Biol 2010, 12:928-929.
108. Wei S., Curiel T., Coukos G., Liu R., Zou W. Inhibitory B7 family members in human ovarian carcinoma. Adv Exp Med Biol 2008, 622:261-271.
109. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
110. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009, 182:5891-5897.
111. Ward S.G., Cantrell D.A. Phosphoinositide 3-kinases in T lymphocyte activation. Curr Opin Immunol 2001, 13:332-338.
112. Jiang K., Zhong B., Gilvary D.L., Corliss B.C., Hong-Geller E., Wei S., et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000, 1:419-425.
113. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
114. Latchman Y.E., Liang S.C., Wu Y., Chernova T., Sobel R.A., Klemm M., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004, 101:10691-10696.
115. Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-3059.
116. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002, 196:851-857.
117. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
118. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
119. Doedens A.L., Phan A.T., Stradner M.H., Fujimoto J.K., Nguyen J.V., Yang E., et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol 2013, 14:1173-1182.
120. Olurinde M.O., Shen C.H., Drake A., Bai A., Chen J. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent. Cell Mol Immunol 2011, 8:415-423.
121. Rossig C., Brenner M.K. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004, 10:5-18.
122. Walker R.E., Bechtel C.M., Natarajan V., Baseler M., Hege K.M., Metcalf J.A., et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000, 96:467-474.
123. Yun C.O., Nolan K.F., Beecham E.J., Reisfeld R.A., Junghans R.P. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000, 2:449-459.
124. Beecham E.J., Ortiz-Pujols S., Junghans R.P. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. J Immunother 2000, 23:332-343.
125. Nolan K.F., Yun C.O., Akamatsu Y., Murphy J.C., Leung S.O., Beecham E.J., et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999, 5:3928-3941.
126. Boyle A.P., Davis S., Shulha H.P., Meltzer P., Margulies E.H., Weng Z., et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008, 132:311-322.
127. Araki Y., Wang Z., Zang C., Wood W.H., Schones D., Cui K., et al. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 2009, 30:912-925.
128. Hassig C.A., Tong J.K., Fleischer T.C., Owa T., Grable P.G., Ayer D.E., et al. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A 1998, 95:3519-3524.
129. Murayama A., Sakura K., Nakama M., Yasuzawa-Tanaka K., Fujita E., Tateishi Y., et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J 2006, 25:1081-1092.
130. Riquet F.B., Tan L., Choy B.K., Osaki M., Karsenty G., Osborne T.F., et al. YY1 is a positive regulator of transcription of the Col1a1 gene. J Biol Chem 2001, 276:38665-38672.
131. Ugel S., Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012, 2:628-639.
132. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007, 13:828-835.
133. Hernandez J., Aung S., Redmond W.L., Sherman L.A. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med 2001, 194:707-717.
134. Youngblood B., Wherry E.J., Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS 2012, 7:50-57.
135. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006, 12:335-341.
136. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.